- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01285856
Hair Testing to Assess Consumption of Illicit Psychotropic Agents and Alcohol by Patients Treated With High-dose Buprenorphine and Methadone. Search for a Pharmacogenetic Contribution to Low Efficacy of Substitution Medications
Justification and aims of the study: The principal aim of use of opiate substitutes such as methadone or high-dose buprenorphine (HDB) is to reduce the need or the desire to consume the opiate to which the patient is addicted. Adjustment of the initial dose and regular re-evaluation of the efficacy of treatment are key elements in the success of such management. While too high a dose can be responsible for side effects leading to abandonment of treatment, too low a dose can induce the reappearance or even the reinforcing of parallel consumption of other psychoactive substances, in particular cocaine, alcohol and cannabis. The principal aim of this project is to determine the course of parallel consumption in patients who have been receiving a maintenance dose of methadone or HDB for at least two months, by analysis of a sample of hair, a biological matrix which is innovative for this type of study. Hair testing establishes a retrospective profile of consumption. The secondary aims of this project are (i) to validate the French versions of Handelsman's subjective and objective opiate withdrawal scales and to seek a possible correlation between high scores on these scales and the presence of parallel consumption, and (ii) to seek an association between polyconsumption and common functional polymorphisms of metabolic enzymes of methadone and HDB.
Expected results: Hair testing, which has the particular advantage of a long detection window so that samples need only be taken at intervals, could improve the biological monitoring of patients on substitutive treatment.
Validation of the French version of Handelsman's scales of objective and subjective signs of opiate withdrawal and search for any correlation with parallel consumption will enable these scales to be used in daily practice for clinical surveillance of patients on substitutive treatment.
If a polymorphism of a metabolic enzyme of one or other of these molecules is detected, rapid genotyping of a simple saliva sample will be valuable in guiding the choice of medication when deciding on a treatment strategy
Study Overview
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Anne Laure Pelissier-Alicot
- Phone Number: +33491384748
- Email: anne-laure.pelissier@ap-hm.fr
Study Locations
-
-
-
Marseille, France, 13005
- Recruiting
- APHM
-
Contact:
- Anne-Laure Pelissier-Alicot
- Phone Number: +33491384748
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- subjects followed for opiates substitute treatment
- patients treated by HDB or methadone for at least two months
- length of hair superior to 2 centimeters
Exclusion Criteria:
- patients treated by HDB or methadone for less than two months
- Patients with clinical signs of intolerance or opioid overdose
- opioid treatments
- neurological or psychiatric disease
- hepatic disease
- pregnancy
- patients in prison
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: buprenorphine
populations of patients treated with HDB will be recruited during consultations at a center for addiction treatment.
One hundred and ten patients will be included.
Written informed consent will be obtained from each patient.
Anonymity will be respected at inclusion and throughout.
Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry.
Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales.
Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
|
Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months. Saliva sample, a method which gives similar results without the need for venous blood sampling. |
Active Comparator: methadone
populations of patients treated with methadone will be recruited during consultations at a center for addiction treatment.
One hundred and ten patients will be included.
Written informed consent will be obtained from each patient.
Anonymity will be respected at inclusion and throughout.
Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry.
Treatment efficacy will also be assessed using Handelsman's subjective and objective opiate withdrawal scales.
Lastly, polymorphisms of the metabolic enzymes of methadone and HDB will be sought by real-time PCR in a saliva sample, a method which gives similar results without the need for venous blood sampling.
|
Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months. Saliva sample, a method which gives similar results without the need for venous blood sampling. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hair ANALYSIS
Time Frame: 36 months
|
Hair testing which has the particular advantage of a long detection window so that samples need only be taken at intervals
|
36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Validation of the French version of Handelsman's scales
Time Frame: 36 months
|
Validation of the French version of Handelsman's scales of objective and subjective signs of opiate withdrawal and search for any correlation with parallel consumption will enable these scales to be used in daily practice for clinical surveillance of patients on substitutive treatment.
|
36 months
|
polymorphism of a metabolic enzyme
Time Frame: 36 months
|
If a polymorphism of a metabolic enzyme of one or other of these molecules is detected, rapid genotyping of a simple saliva sample will be valuable in guiding the choice of medication when deciding on a treatment strategy.
|
36 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Anne-Laure Pelissier-Alicot, APHM
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2010-A00256-33 (Other Identifier: DRC)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Substance Abuse
-
The Morton Center, Inc.National Institute on Alcohol Abuse and Alcoholism (NIAAA)UnknownAlcohol Dependence | Cannabis Dependence | Alcohol Abuse | Cannabis Abuse | Other Substance AbuseUnited States
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)United States
-
Michael E. DeBakey VA Medical CenterUnknownAlcohol Dependence | Alcohol Abuse | Substance Abuse ProblemUnited States
-
National Health Promotion Associates, Inc.UnknownSubstance Use | Substance Abuse | Prescription Drug Abuse (Not Dependent)
-
National Institute on Drug Abuse (NIDA)CompletedDrug/Substance Abuse/Addiction | Alcohol Abuse/AddictionUnited States
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedSubstance Abuse, IntravenousUnited States
-
Sheidow Consulting, Inc.Oregon Social Learning CenterCompletedSubstance Abuse ProblemUnited States
-
Penn State UniversityCompletedSubstance Abuse ProblemUnited States
-
National Institute on Drug Abuse (NIDA)CompletedSubstance Abuse | Drug Abuse | Alcohol AbuseUnited States
-
University of California, IrvineUS Department of Veterans AffairsWithdrawn
Clinical Trials on hair and saliva samples
-
Gustave Roussy, Cancer Campus, Grand ParisUnknownPaediatric MalignanciesFrance
-
University Hospital, GrenobleTerminatedChronic Granulomatous DiseaseFrance
-
Cairo UniversityUnknownPatients With Oral Lichen PlanusEgypt
-
University Hospital, ToulouseRecruiting
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
University of BelgradeNot yet recruiting
-
Memorial Sloan Kettering Cancer CenterTel-Aviv Sourasky Medical Center; Sheba Medical Center; Princess Alexandra Hospital...Active, not recruitingHigh-Risk Nevus PhenotypeUnited States
-
University Hospital, BordeauxRecruitingBehavioral Symptoms | Mental Disorders | Depression | Brain Diseases | Neurocognitive Disorders | Dementia | Anxiety | Alzheimer Disease | Aging | Mental Health | Immunosenescence | Cognition | Brain | Cognitive Aging | Mental ProcessesFrance
-
University Hospital, ToulouseUniversity Paul Sabatier of ToulouseTerminated
-
Memorial Sloan Kettering Cancer CenterSusan G. Komen Breast Cancer Foundation; Jewish Home & Hospital Lifecare System and other collaboratorsCompletedNon-cancer Affected VolunteersUnited States